Optometry Times, Digital Edition, March 2012

Article

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Related Content
Voluntary recall for potentially hazardous eye drops - Image credit:©Kwangmoozaa—stock.adobe.com

Potentially hazardous eye care products recalled nationwide

Lynda Charters
May 12th 2025
Article
New Opportunities in Topical Glaucoma Management

New Opportunities in Topical Glaucoma Management

Mitch Ibach, OD, FAAO;Jessica Steen, OD, FAAO
January 31st 2025
Podcast
Two scientists discussing data in lab Image credit: AdobeStock/peopleimages.com

ARVO 2025: Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma

Jordana Joy, Associate Editor
May 9th 2025
Article
You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

Miriam Korik, OD;Tiffany Tsoi, OD;Emily Kaiser Maharjan, Assistant Managing Editor
December 4th 2024
Podcast
Cognition Therapeutics publishes topline results of oral candidate zervimesine for the treatment of geographic atrophy - Image credit: ©Milan—stock.adobe.com

Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

Emily Kaiser Maharjan, Assistant Managing Editor
May 8th 2025
Article
Boehringer advances 2 geographic atrophy candidates to phase 2 clinical trials - Image credit: ©Dzmitry—stock.adobe.com

Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

Emily Kaiser Maharjan, Assistant Managing Editor
May 8th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.